Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 11.08M | $29.0M | 9.89% | +7.08M | 2026-03-31 |
| Bain Capital Life Sciences Investors, LLC | 9.68M | $26.0M | 8.64% | -- | 2026-03-31 |
| JENNISON ASSOCIATES LLC | 8.97M | $24.0M | 8.01% | +64.9K | 2026-03-31 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 8.83M | $23.0M | 7.88% | -- | 2026-03-31 |
| MILLENNIUM MANAGEMENT LLC | 5.90M | $15.0M | 5.27% | +3.17M | 2026-03-31 |
| Cormorant Asset Management, LP | 5.50M | $14.0M | 4.91% | +1.10M | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.03M | $10.0M | 3.60% | -- | 2026-03-31 |
| BlackRock, Inc. | 2.37M | $6.0M | 2.12% | +44.5K | 2026-03-31 |
| MARSHALL WACE, LLP | 2.18M | $5.0M | 1.95% | +1.22M | 2026-03-31 |
| RENAISSANCE TECHNOLOGIES LLC | 2.04M | $5.0M | 1.82% | +514.1K | 2026-03-31 |
